Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Bristol Myers Squibb: Clinical Trials & FDA Approval Profile

Bristol Myers Squibb (Princeton, NJ) sponsors 272 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 132 active protocols (69 recruiting now), 88 completed protocols, and 78 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)19.1%
Median Closed Enrollment vs National (145 pts)160 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Bristol Myers Squibb
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)272
Active Pipeline (Recruiting Now)132 (69)
Completed vs Stopped Early88 / 52 (19.1%)
Median Closed Actual Enrollment160 participants
Physical Hospital Site Disclosure97.3% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals78 (14 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Bristol Myers Squibb
Hospital Research SiteLocationShared Protocols
Hospital Universitario 12 de OctubreMadrid24
Asan Medical CenterSeoul21
Hospital Universitari Vall d'HebronBarcelona19

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Bristol Myers Squibb
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06615479A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and LenaPhase IIIRECRUITING
NCT04613596Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients WitPhase II/IIIRECRUITING
NCT06869551A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile PsoriaticPhase IIIRECRUITING
NCT04143724Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaPhase IIRECRUITING
NCT06646276A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin PlusPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Bristol Myers Squibb Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI